Download PDF

1. Company Snapshot

1.a. Company Description

Lucid Diagnostics Inc.operates as a commercial-stage medical diagnostics technology company.The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.


Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device.The company was incorporated in 2018 and is based in New York, New York.Lucid Diagnostics Inc.


is a subsidiary of PAVmed Inc.

Show Full description

1.b. Last Insights on LUCD

Lucid Diagnostics' recent performance was driven by several positive factors. The company processed a record 4,042 EsoGuard tests in 4Q24, a 45% sequential and 84% annual increase, resulting in recognized EsoGuard revenue of $1.2 million in 4Q24. Additionally, Lucid secured its first agreement to pay for EsoGuard under state biomarker legislation, indicating growing acceptance of its technology. The company also established a new sales channel, generating over 20 new cash-pay concierge medicine contracts. Furthermore, Lucid regained compliance with the Nasdaq minimum bid price requirement, demonstrating its ability to navigate regulatory challenges.

1.c. Company Highlights

2. Lucid Diagnostics Q4 2025: Surge in Volume, VA Deal, and Medicare Momentum

Lucid Diagnostics Inc. delivered a robust fourth‑quarter performance, reporting $1.5 million in revenue—up 24% sequentially—and a 29% jump in EsoGuard test volumes to 3,664 units, surpassing the 2,500‑3,000 target range. The company posted a non‑GAAP loss of $44 million, or $0.43 per share, compared to an analyst estimate of –$0.07. With a P/E ratio of –2.02 and an EV/EBITDA of 6,146.5, the stock trades in a steep discount, reflecting the heavy operating burn and pending Medicare coverage. One staff analyst noted that the VA Federal Supply Schedule contract at $938 per test is a “high‑impact driver” for scaling the business.

Publication Date: Apr -13

📋 Highlights
  • Test Volume Growth:: 3,664 EsoGuard tests in Q4 2025, a 29% sequential increase and exceeding the 2,500-3,000 target range.
  • Revenue Growth:: Revenue reached $1.5 million, a 24% sequential rise, with $9 million in billable value from 3,600+ tests.
  • VA Contract Secured:: EsoGuard added to VA FSS at Medicare rate of $938, targeting 9 million veterans annually at higher GERD risk.
  • Study Success Rates:: EsoCheck achieved 95% technical success rate, with 95% of procedures completed under two minutes in 12,000-patient study.
  • Cash Position & Burn Rate:: $34.7 million cash at year-end, with $11.1 million average quarterly burn and 80% of billable amounts pending collection.

Revenue Growth

Quarterly sales rose to 3,664 EsoGuard tests, generating $1.5 million in recognized revenue and $9 million in billable value, marking a 24% sequential increase. The company’s real‑world study of 12,000 patients validated the high technical success of EsoCheck, supporting future upsell and cross‑sell opportunities.

Operating Losses

Total operating expenses climbed to $48.7 million, driven by a $5 million sales and marketing spend that grew 25% quarter‑over‑quarter. The non‑GAAP loss of $44 million underscores the company’s investment‑heavy growth phase, with a burn rate of $11.1 million per quarter.

Reimbursement Landscape

Forty‑nine percent of Q4 revenue came from prior‑quarter claims, with 76% of new claims adjudicated and 24% pending. Medicare now accounts for 16% of test volume, up from 10‑12% in earlier quarters, and the firm expects a sizable lift once the final policy is adopted.

VA and Medicare Opportunities

The VA FSS contract opens access to 9 million veterans, a population with elevated GERD risk. Lucid’s national and local VA sales teams aim to secure physician champions at each center, translating lessons learned into revenue growth.

Payer Strategy

Lucid has secured coverage from UnitedHealthcare and a positive LBM policy, while actively negotiating with the Blue Cross Blue Shield Association and integrated delivery networks. The company plans to measure Medicare sales rep productivity in 2026.

Sales & Marketing Spend

Marketing expenses rose $1 million quarter‑over‑quarter to $5 million, a level deemed sustainable given the company’s current capital‑market constraints and the need to maintain pipeline velocity.

Cash Position & Burn

Year‑end cash stood at $34.7 million against a quarterly burn of $11.1 million, leaving a runway of roughly three quarters if burn continues unchanged.

Outlook & Valuation

Analysts project 2026 revenue growth of 130.5%. With a steep discount in P/E and EV/EBITDA, the market has priced in the risk of delayed Medicare coverage, but the VA and payer wins suggest a potential upside as the company scales.

3. NewsRoom

Card image cap

Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference

Apr -09

Source: prnewswire.com

Card image cap

PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio

Apr -02

Source: prnewswire.com

Card image cap

PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar -30

Source: prnewswire.com

Card image cap

Lucid Diagnostics Q4 Earnings Call Highlights

Mar -28

Source: defenseworld.net

Card image cap

Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $3.94 Consensus PT from Brokerages

Mar -27

Source: defenseworld.net

Card image cap

Lucid Diagnostics Inc. (LUCD) Q4 2025 Earnings Call Transcript

Mar -26

Source: seekingalpha.com

Card image cap

Lucid Diagnostics Inc. (LUCD) Reports Q4 Loss, Beats Revenue Estimates

Mar -26

Source: zacks.com

Card image cap

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar -26

Source: prnewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.02%)

6. Segments

Medical Diagnostics Technology

Expected Growth: 10.02%

Lucid Diagnostics Inc.'s Medical Diagnostics Technology growth is driven by increasing demand for non-invasive diagnostic tests, advancements in AI-powered diagnostics, and rising healthcare expenditure. The growing need for early disease detection, prevention, and personalized medicine also contributes to this growth. Additionally, the company's innovative technology and strategic partnerships have enabled it to capitalize on these trends, resulting in a 10.02% growth rate.

7. Detailed Products

EsoGuard Esophageal DNA Test

A non-invasive, swallowable capsule that collects cells from the esophagus to detect Barrett's esophagus and esophageal cancer

EsoCheck Esophageal Cell Collection Device

A non-invasive, office-based device that collects cells from the esophagus for diagnostic testing

LucidDx Esophageal Diagnostic Platform

A comprehensive platform that combines EsoGuard and EsoCheck with advanced analytics and machine learning to aid in the diagnosis and management of esophageal disease

8. Lucid Diagnostics Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Lucid Diagnostics Inc. has a low threat of substitutes due to its unique and patented technology in the field of cancer diagnostics.

Bargaining Power Of Customers

Lucid Diagnostics Inc. has a medium bargaining power of customers due to the presence of a few large hospital chains and research institutions that can negotiate prices.

Bargaining Power Of Suppliers

Lucid Diagnostics Inc. has a low bargaining power of suppliers due to the availability of multiple suppliers for the necessary raw materials and equipment.

Threat Of New Entrants

Lucid Diagnostics Inc. has a high threat of new entrants due to the growing demand for cancer diagnostics and the potential for new companies to enter the market.

Intensity Of Rivalry

Lucid Diagnostics Inc. has a medium intensity of rivalry due to the presence of a few established players in the market, but with opportunities for differentiation and growth.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 117.85%
Debt Cost 3.95%
Equity Weight -17.85%
Equity Cost 11.38%
WACC 2.62%
Leverage -660.10%

11. Quality Control: Lucid Diagnostics Inc. passed 1 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
PetVivo Holdings

A-Score: 4.6/10

Value: 6.2

Growth: 6.0

Quality: 4.8

Yield: 0.0

Momentum: 10.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Lucid Diagnostics

A-Score: 3.6/10

Value: 6.0

Growth: 3.9

Quality: 2.2

Yield: 0.0

Momentum: 7.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
PAVmed

A-Score: 3.6/10

Value: 9.8

Growth: 7.7

Quality: 3.3

Yield: 0.0

Momentum: 0.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Spectral AI

A-Score: 3.6/10

Value: 9.2

Growth: 3.2

Quality: 5.6

Yield: 0.0

Momentum: 2.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Asensus Surgical

A-Score: 3.5/10

Value: 6.7

Growth: 4.4

Quality: 3.5

Yield: 0.0

Momentum: 6.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Strata Skin Sciences

A-Score: 2.4/10

Value: 8.0

Growth: 2.1

Quality: 3.6

Yield: 0.0

Momentum: 0.0

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

1.41$

Current Price

1.41$

Potential

-0.00%

Expected Cash-Flows